DRM01: Phase IIb data

Top-line data from a double-blind, U.S. and Canada Phase IIb trial in 420 patients with moderate to severe facial acne vulgaris showed that twice-daily

Read the full 244 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE